KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short-term Investments: 2020-2025

Historic Short-term Investments for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $3.1 million.

  • Recursion Pharmaceuticals' Short-term Investments rose 101.67% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 101.67%. This contributed to the annual value of $3.0 million for FY2024, which is 5.76% down from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Short-term Investments is $3.1 million, which was up 0.97% from $3.1 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Short-term Investments high stood at $231.4 million for Q4 2021, and its period low was $1.3 million during Q4 2022.
  • For the 3-year period, Recursion Pharmaceuticals' Short-term Investments averaged around $2.6 million, with its median value being $3.1 million (2025).
  • In the last 5 years, Recursion Pharmaceuticals' Short-term Investments skyrocketed by 11,472.30% in 2021 and then tumbled by 99.45% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Short-term Investments (Quarterly) stood at $231.4 million in 2021, then plummeted by 99.45% to $1.3 million in 2022, then spiked by 152.42% to $3.2 million in 2023, then decreased by 5.76% to $3.0 million in 2024, then surged by 101.67% to $3.1 million in 2025.
  • Its Short-term Investments stands at $3.1 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.1 million for Q1 2025.